Daunorubicin + Cytarabine + Venetoclax in de Novo AML
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
This study is a non-profit, prospective, single-center, open-label, controlled clinical trial aimed at evaluating the efficacy of the daunorubicin, cytarabine, and venetoclax (DAV) regimen in previously untreated adult AML patients eligible for intensive chemotherapy.The combination of daunorubicin administered for 3 consecutive days and cytarabine for 7 consecutive days constitutes the classic "3+7" induction chemotherapy regimen for AML patients eligible for chemotherapy. The addition of venetoclax to the "3+7" regimen has shown promising efficacy in newly diagnosed AML patients suitable for intensive therapy. However, this approach is associated with increased adverse reactions. Based on current clinical studies, we propose a modified approach involving reduced-dose chemotherapy combined with venetoclax for AML treatment, aiming to achieve optimal efficacy while effectively reducing adverse reactions.
Phase:
NA
Details
Lead Sponsor:
Anhui Medical University
Collaborator:
The First Affiliated Hospital of Anhui Medical University